|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/133 | |
| A61K 31/135 | |||
| A61K 31/00 | |||
| A61K 45/06 | |||
| A61K 31/661 | |||
| A61P 25/28 |
| (11) | Number of the document | 2213285 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09177200.4 |
| Date of filing the European patent application | 2004-12-17 | |
| (97) | Date of publication of the European application | 2010-08-04 |
| (45) | Date of publication and mention of the grant of the patent | 2013-11-06 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 0329498 | 2003-12-19 | GB |
| (72) |
Brinkmann, Volker, DE
Kaneider, Nicole, AT
Wiedermann, Christian J., AT
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
Novartis Pharma GmbH, Brunner Strasse 59, 1230 Wien, AT |
| (54) | Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases |
| Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases |